Thomas Dumortier

1.4k total citations
22 papers, 585 citations indexed

About

Thomas Dumortier is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Transplantation. According to data from OpenAlex, Thomas Dumortier has authored 22 papers receiving a total of 585 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Surgery, 4 papers in Cardiology and Cardiovascular Medicine and 4 papers in Transplantation. Recurrent topics in Thomas Dumortier's work include Renal Transplantation Outcomes and Treatments (4 papers), Statistical Methods in Clinical Trials (4 papers) and Blood Pressure and Hypertension Studies (3 papers). Thomas Dumortier is often cited by papers focused on Renal Transplantation Outcomes and Treatments (4 papers), Statistical Methods in Clinical Trials (4 papers) and Blood Pressure and Hypertension Studies (3 papers). Thomas Dumortier collaborates with scholars based in Switzerland, United States and France. Thomas Dumortier's co-authors include Lennart Minthon, Jean‐Marc Orgogozo, Bengt Winblad, Kaj Blennow, Niels Andreasen, Ana Graf, R. P. Maguire, Georges Imbert, Matthias Staufenbiel and Ronald D. Smith and has published in prestigious journals such as Journal of Clinical Investigation, The Lancet Neurology and Transplantation.

In The Last Decade

Thomas Dumortier

18 papers receiving 560 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Dumortier Switzerland 9 232 123 121 100 90 22 585
Teruhiko Matsushima Japan 14 192 0.8× 209 1.7× 36 0.3× 108 1.1× 25 0.3× 40 717
G. Tibolla Italy 13 103 0.4× 256 2.1× 47 0.4× 115 1.1× 24 0.3× 21 1.1k
Carol Cronenberger United States 13 135 0.6× 67 0.5× 101 0.8× 11 0.1× 34 0.4× 28 540
David Han United States 13 118 0.5× 102 0.8× 104 0.9× 29 0.3× 8 0.1× 28 557
Chien‐Wei Chiang United States 11 99 0.4× 286 2.3× 58 0.5× 20 0.2× 37 0.4× 34 669
Julie Newton United States 16 119 0.5× 277 2.3× 44 0.4× 30 0.3× 50 0.6× 26 664
Nancy A. Pyszczynski United States 17 62 0.3× 271 2.2× 41 0.3× 18 0.2× 21 0.2× 20 694
Guowei Zhou China 15 62 0.3× 226 1.8× 66 0.5× 34 0.3× 14 0.2× 44 620
Olga Bushueva Russia 19 155 0.7× 300 2.4× 14 0.1× 69 0.7× 17 0.2× 76 716
Wendell-Lamar B. Blackwell United States 8 38 0.2× 176 1.4× 35 0.3× 159 1.6× 12 0.1× 8 458

Countries citing papers authored by Thomas Dumortier

Since Specialization
Citations

This map shows the geographic impact of Thomas Dumortier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Dumortier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Dumortier more than expected).

Fields of papers citing papers by Thomas Dumortier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Dumortier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Dumortier. The network helps show where Thomas Dumortier may publish in the future.

Co-authorship network of co-authors of Thomas Dumortier

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Dumortier. A scholar is included among the top collaborators of Thomas Dumortier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Dumortier. Thomas Dumortier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bretz, Frank, Björn Bornkamp, & Thomas Dumortier. (2025). Dose-response characterization: A key to success in drug development. Clinical Trials. 22(4). 384–392.
2.
Dumortier, Thomas, Guillermo J. Valenzuela, Melvin Churchill, et al.. (2025). Model‐Informed Drug Development‐Based Bridging from Subcutaneous to Intravenous Secukinumab Dosing: Approval in Psoriatic Arthritis and Axial Spondyloarthritis. Clinical Pharmacology & Therapeutics. 118(2). 480–488.
3.
Kivitz, Alan, Melvin Churchill, Atul Singhal, et al.. (2024). Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase 3 Study. Arthritis & Rheumatology. 77(2). 171–179. 1 indexed citations
4.
Klein, Amanda, Alexandre Loupy, Mark D. Stegall, et al.. (2023). Qualifying a novel clinical trial endpoint (iBOX) predictive of long-term kidney transplant outcomes. American Journal of Transplantation. 23(10). 1496–1506. 14 indexed citations
5.
Klein, Amanda, Alexandre Loupy, Mark D. Stegall, et al.. (2023). Qualifying a Novel Clinical Trial Endpoint (iBOX) Predictive of Long-Term Kidney Transplant Outcomes. Transplant International. 36. 11951–11951. 8 indexed citations
6.
Akacha, Mouna, Christian Bartels, Björn Bornkamp, et al.. (2021). Estimands—What they are and why they are important for pharmacometricians. CPT Pharmacometrics & Systems Pharmacology. 10(4). 279–282. 8 indexed citations
7.
Dumortier, Thomas, et al.. (2021). Exposure‐response modeling for extrapolation from adult to pediatric patients who differ with respect to prognostic factors: Application to everolimus. CPT Pharmacometrics & Systems Pharmacology. 10(6). 589–598. 3 indexed citations
8.
Dumortier, Thomas, Michael Looby, Olivier Luttringer, et al.. (2015). Estimating the contribution of everolimus to immunosuppressive efficacy when combined with tacrolimus in liver transplantation: A model‐based approach. Clinical Pharmacology & Therapeutics. 97(4). 411–418. 4 indexed citations
9.
Dumortier, Thomas, et al.. (2014). Chronique de droit des discriminations (octobre 2014-avril 2015). Revue des droits de l’homme. 3 indexed citations
10.
Dumortier, Thomas, et al.. (2014). Chronique de droit des discriminations (mai 2015-septembre 2015). Revue des droits de l’homme.
11.
Junge, G., Thomas Dumortier, H. Schwende, & John J. Fung. (2013). mTOR Inhibition in Liver Transplantation: How to Dose for Effective/Safe CNI Reduction?. Transplantation Proceedings. 45(5). 1979–1980. 2 indexed citations
12.
Winblad, Bengt, Niels Andreasen, Lennart Minthon, et al.. (2012). Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. The Lancet Neurology. 11(7). 597–604. 234 indexed citations
13.
Séchaud, Romain, et al.. (2009). Deferasirox does not induce QT/QTc-prolongation in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics. 47(5). 321–327. 9 indexed citations
14.
Skvara, Hans, Markus Dawid, Barbara Wolff, et al.. (2008). The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. Journal of Clinical Investigation. 118(9). 3151–3159. 128 indexed citations
15.
Séchaud, Romain, et al.. (2008). Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks. International Journal of Clinical Pharmacology and Therapeutics. 46(2). 102–108. 18 indexed citations
16.
Dumortier, Thomas, et al.. (2008). NVP-AEB071 MAXIMUM TOLERATED DOSE: SAFETY AND TOLERABILITY OF A NOVEL T-CELL ACTIVATION INHIBITOR. Transplantation. 86(2S). 412–412. 1 indexed citations
17.
Manolis, Athanasios, Ehud Grossman, Bojan Jelaković, et al.. (2000). Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Clinical Therapeutics. 22(10). 1186–1203. 77 indexed citations
18.
Mejia, Alfonso, Walter Cabrera, Bojan Jelaković, et al.. (2000). LOSARTAN AND CANDESARTAN PRODUCE COMPARABLE BLOOD PRESSURE REDUCTIONS BUT ONLY LOSARTAN LOWERS PLASMA URIC ACID IN HYPERTENSIVE PATIENTS. Journal of Hypertension. 18. S99–S99.
19.
Monterroso, Víctor H., Gustavo Aroca, G Hitzenberger, et al.. (2000). Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Advances in Therapy. 17(2). 117–131. 29 indexed citations
20.
Sareli, Pinhas, Francisco Marı́n, Gustavo Aroca, et al.. (2000). Increased efficacy and tolerability with losartan plus hydrochlorothiazide in patients with uncontrolled hypertension and therapy-related symptoms receiving two monotherapies.. PubMed. 16(5). 187–99. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Teruhiko Matsushima Breakdown of academic impact, for papers by G. Tibolla Breakdown of academic impact, for papers by Carol Cronenberger Breakdown of academic impact, for papers by David Han Breakdown of academic impact, for papers by Chien‐Wei Chiang Breakdown of academic impact, for papers by Julie Newton Breakdown of academic impact, for papers by Nancy A. Pyszczynski Breakdown of academic impact, for papers by Guowei Zhou Breakdown of academic impact, for papers by Olga Bushueva Breakdown of academic impact, for papers by Wendell-Lamar B. Blackwell
Rankless by CCL
2026